Kolkata : Elekta announced the introduction of its latest linear accelerator
(linac), Evo*, to the Indian market. Already launched in Europe and other
regions, Evo is now available in India, bringing high-definition AI-enhanced
imaging and its adaptive radiation therapy capabilities to clinicians across
the country. This highly versatile CT-Linac will enable clinicians to choose
the most suitable radiation therapy technique for each individual patient. Evo
was showcased for the first time in India at the Association of Radiation
Oncologists of India Conference (AROICON) in Kolkata, the country’s largest
industry exhibition in radiation oncology.
Feras Al
Hasan, Head of TIMEA, Elekta said: “We are delighted to bring our flagship
innovation Evo Elekta to India. Evo
brings a new level of flexibility to India’s radiotherapy landscape and is
designed to help centres deliver more personalized, efficient care. Its ability
to support both online and offline adaptive treatments on a CT-Linac gives
clinicians the confidence to adjust therapy based on daily anatomical changes
which is especially important in India, where many patients present with
complex and advanced stage diseases. Our aim is to strengthen Elekta’s
commitment to making high-quality cancer treatment accessible to more patients
across the globe.”
Shankar
Seshadri, VP & Head - India Sub-continent, added: “India needs
radiotherapy solutions that combine precision with practicality and Evo is
uniquely positioned to address India’s growing cancer burden and evolving
patient needs. Its adaptive capabilities and streamlined workflow help
high-volume centres treat more patients without compromising treatment quality.
The arrival of Evo in India marks a significant milestone, as it will help
accelerate our market growth in the region.”
Adaptive radiotherapy, also known as Adaptive
Radiation Therapy or ART, is a treatment approach in which the radiation plan
is adjusted over the course of therapy to account for changes in a patient’s
unique anatomy and or tumor. Delivering this therapy requires high-quality
imaging that enables clinicians to visualize tumors and organs at risk,
ensuring precise contouring. Evo helps address this need with two essential
features: Iris®™ high-definition, AI-enhanced imaging, which allows
visualization of target areas with greater clarity, and Elekta ONE Online**
software, which brings distributed treatment planning, faster dose calculation
and AI-driven automation for contouring and dose planning.
*Elekta Evo has Central Drugs Standard
Control Organization (CDSCO) registration with limited global availability.
**Elekta ONE® is comprised of multiple Elekta
solutions, some of which may not yet be available in all markets.
No comments:
Post a Comment